One of state’s last life science unicorns gets 2nd shot from FDA

Intarcia Therapeutics is hoping, finally, to launch its matchstick-sized diabetes pump — two years after an FDA rejection threw the company for a loop. Type 2 diabetes affects roughly 27 million Americans.